Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by jfm1330on Jul 23, 2022 3:23pm
278 Views
Post# 34845664

Canadian technology

Canadian technology
We had an ignorant here not so long ago complaining about Thera being a Canadian company. This was totally ridiculous. This country, for its size, is as good as any advanced country. A lot of good research is made in Canada. Look at this video from Canadian Nuclear Laboratories, about the production of medical grade Actinium 225. This radioisotope is the next big thing in nuclear therapies against cancers.

Look also at the third link. It is a short presentation by a doctor from Vancouver about the use of actinium 225 instead of Lu177 in eithe neuroendocrine tumors or prostate cancer. Results are simply spectacular. Just imagine if SORT1+ platform concept is fully validated. Imagine future  PDCs with actinium 225. This is not science fiction. All parts of these potential PDCs exist now.

I know it cannot happen rapidly, but it shows the incredible potential SORT1+ could have with a much more potent cytotoxic agent than docetaxel. That's why the formal proof of concept is so critical and there is no patent on actinium 225. Thera could develop a new PDC that they would totally own. Also, imagine what it is for a patient like me to see these results. If need be I will go to India to have it, but I hope it could be available in Canada in a few years. The fight against cancer is really progressing fast on many fronts. There is hope.
 
https://www.youtube.com/watch?v=MjL_LJm8CqI
 
https://www.cnl.ca/health-science-2/actinium-225/ 

https://www.youtube.com/watch?v=A3tpUKgf7gQ
 
<< Previous
Bullboard Posts
Next >>